Navigation Links
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Date:1/6/2014

ocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's VMAT2 program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's VMAT2 program include, but are not limited to; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate partners for development, commercial manufacturing and marketing and sales activities for the Company's partnered programs; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2012 and on Form 10-Q for the quarter ended September 30, 2013. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
3. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
4. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
5. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
6. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
7. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
8. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
9. Neurocrine Biosciences Reports First Quarter 2013 Results
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... of regulatory and marketplace changes. CI leaders who adjust ... In a new Best Practices, LLC study ... of actionable insights, including: - Use secondary ... than primary research - Internal staff who ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PRNewswire/ ... Medina Medical as CEO and member of the Board ... three decades of medical device development and commercialization experience, ... Medical,s field. Mr. Engelson previously served as a Partner ... served as President and CEO of two Foundry start-ups. ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... 23 SurgiCount Medical, the wholly-owned operating subsidiary ... PSTX ), announced that results of ... Clinic on their multi-year effort to reduce retained ... two upcoming conferences.  The research and related discussion ...
... Agreement to Develop and... -- ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Mayo Clinic Research on SurgiCount To Be Presented at Conferences 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 3Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 4Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 5Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 6Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 7Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 8Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 9
(Date:8/29/2014)... August 29, 2014 As reported by WKMS.com ... Recovery , an Ohio municipal court drug has come up ... Fred Moses, who serves as the presiding judge in a ... makers to offer addicts a medicated treatment option that can ... the drug known as Vivitrol, which blocks receptors in the ...
(Date:8/29/2014)... 29, 2014 According to new research presented ... Peer Pressure, Key to Prescription Drug Misuse Among Young Adults ... for 18-29 year olds when it comes to prescription drug ... this age group the real problem which influences misuse of ... and recreational use of them to have fun with other ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... 2014 Healthpointe has unveiled its new ... the convenience of visiting with physicians online. Anyone can ... , Healthpointe doctors are always available and happy to ... the doctor can even see the patient’s entire family. ... or she can prescribe medications that are available for ...
(Date:8/29/2014)... August 29, 2014 Healthpointe is ... University Physical Therapy students via Clinical Rotations. ... will be shadowing Healthpointe providers and specialists throughout ... to develop clinical experience and learn professional preparation. ... will gain insight into several patient care techniques ...
Breaking Medicine News(10 mins):Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2
... , BOYNTON BEACH, Fla. , Feb. ... of this year,s US Open Men,s and Women,s tennis tournament ... http://www.newscom.com/cgi-bin/prnh/20100209/DC52484 ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20100120/DC41252LOGO-b ) , Would you ... Golf tournament, complete with airfare and accommodations? , Would you ...
... INDIANAPOLIS -- In the first large-scale epidemiological study of ... researchers from the Indiana University School of Medicine and ... 2010 issue of The Journal of Trauma Injury, ... and opportunities for prevention of these injuries. Nearly ...
... Medical Center are offering pediatric patients diagnosed with chronic ... negative side effects like nausea, fatigue, and vomiting caused ... confluence of Chinese and Western medicine at Rush Children,s ... document how acupuncture might help in reducing pain in ...
... ... Collection Manager™ increases patient safety through accuracy and timeliness , ... (PRWEB) February 9, 2010 ... outreach solutions, announced today that the University of Virginia Health System Medical Laboratories, ...
... D begins in the womb, expert says, , TUESDAY, Feb. ... lots of milk and have a high dietary intake of ... developing multiple sclerosis later in life, researchers say. , The ... about their experiences and diet during pregnancy. The nurses were ...
... , Consumer Watchdog Also Warns Against Insurer-favored ,Cost Solution,: ... Apartment" , WASHINGTON , Feb. 9 ... its premium hikes of up to 39% in California , ... House and an investigation by California ,s insurance commissioner, federal ...
Cached Medicine News:Health News:Would You Like to Own a Thriller Album Autographed by Michael Jackson Himself? 2Health News:Watch your step: Elevator-related injuries and older adults 2Health News:Watch your step: Elevator-related injuries and older adults 3Health News:Young patients with chronic illnesses find relief in acupuncture 2Health News:University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution 2Health News:University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution 3Health News:Drinking Milk While Pregnant May Lower Kids' MS Risk 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3
One channel transcranial Doppler...
Flagship Transcranial Doppler system with multiple channel options, multi-depth options....
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
... fine tips and are intended for the most ... The curved ones are ideal for tweezing out ... student versions are for beginners. These Dumont/Swiss watchmaker ... The Swiss forceps are made from the highest ...
Medicine Products: